Latest news with #PaulBrooks
BBC News
4 days ago
- Health
- BBC News
First designs for the new QEH hospital in King's Lynn revealed
First designs for a new hospital will go on display at a series of public events, starting this vision for the new Queen Elizabeth Hospital (QEH) in King's Lynn - which will be built on the current hospital's car park - will include single rooms for all a Reinforced Autoclaved Aerated Concrete (RAAC) hospital, the QEH has been prioritised for rebuild by the national New Hospital new building is being developed using national guidance from the New Hospital Programme, developed in consultation with hundreds of clinicians, healthcare staff and patients across the country, the NHS trust said. Paul Brooks, director of estates and facilities for the new QEH, said the visuals would give people "a feel for how our new, digitally enabled, hospital will function"."I look forward to meeting as many people as possible at these events, updating on our progress towards a New QEH and the work to keep our current site open and providing the best possible care."Attendees will have the chance to hear more about the new multi-storey car park, which is a key enabling project for the new hospital. Peter Cox, programme director for the new hospital, said feedback would shape the hospital's designs "as we do know there are concerns" with the new build."At this stage they are really concept," he said."We will go through a process over the next 12 to 18 months, then have a set of plans that we can go for planning application for."Experts attending meetings will also explain how services will be developed for the new building, including preparing departments for the move and the healthcare innovations being explored to meet the needs of the local population for generations to are being held at seven locations in west Norfolk from 10 June until 21 July. Follow Norfolk news on BBC Sounds, Facebook, Instagram and X.
Yahoo
23-04-2025
- Business
- Yahoo
CN Bio and Pharmaron Establish Long-Term Strategic Partnership to Develop OOC Technologies on a Global R&D Platform
Partnership to validate and promote the application of CN Bio's PhysioMimix technology, with future opportunities for novel application and assay development CAMBRIDGE, England, April 23, 2025--(BUSINESS WIRE)--CN Bio, a leading provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, today announced the establishment of a strategic partnership with Pharmaron, a premier R&D service provider for the life sciences industry. Under the agreement, Pharmaron will validate CN Bio's PhysioMimix® technology across existing applications and collaborate on integrating OOC technologies into its R&D platform. The partnership will also explore the development of new applications to address unmet needs in drug discovery and development. The initial phase of the collaboration will focus on validating CN Bio's PhysioMimix technology for current applications in disease modelling, toxicity testing and absorption, distribution, metabolism and excretion (ADME) studies. Following successful validation, the companies will work together to adopt the platform in priority R&D areas and co-develop novel applications to expand the capabilities of OOC technologies. Pharmaron is a global drug R&D service platform, providing end-to-end services across drug discovery, preclinical, and clinical development. Through the partnership, CN Bio will install PhysioMimix instruments at Pharmaron's facilities across the globe, enabling the joint development of cutting-edge OOC solutions tailored to evolving R&D challenges. Dr Paul Brooks, CEO, CN Bio, said: "Pharmaron is a global, premier and trusted service provider for the life sciences industry. As such, Pharmaron were the ideal partner for CN Bio as we look to accelerate the growth of our OOC solutions portfolio in new and existing application areas. By working closely together and leveraging the industry-leading expertise of each company, we can share resources that enable us to progress new, innovative solutions from concept to global market deployment more effectively than ever before. Dr Tomasz Kostrzewski, CSO, CN Bio, commented: "The developments this partnership will enable are especially important given the recent FDA announcement, outlining their plan to phase out animal testing requirement for monoclonal antibodies and other drugs with more human-relevant models. Our platform is best placed to serve current market gaps including testing for immune-mediated organ damage. Together we can expedite this key development in line with global momentum for more ethical advancements that reduce costs and improve human health." Dr Hua Yang, CSO, Pharmaron, added: "We are committed to continuous innovation that enhances the quality of our services and accelerates drug discovery and development. Organ-on-a-chip technology holds significant potential to advance translational science by improving our understanding of drugability at the preclinical stage. We are pleased to collaborate with CN Bio to explore how this technology can add meaningful value to our partners' development programs." View source version on Contacts Zyme Communications Lily JefferyTel: +44(0)7891477378Email: Sign in to access your portfolio
Business Wire
23-04-2025
- Business
- Business Wire
CN Bio and Pharmaron Establish Long-Term Strategic Partnership to Develop OOC Technologies on a Global R&D Platform
CAMBRIDGE, England--(BUSINESS WIRE)--CN Bio, a leading provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, today announced the establishment of a strategic partnership with Pharmaron, a premier R&D service provider for the life sciences industry. Under the agreement, Pharmaron will validate CN Bio's PhysioMimix ® technology across existing applications and collaborate on integrating OOC technologies into its R&D platform. The partnership will also explore the development of new applications to address unmet needs in drug discovery and development. The initial phase of the collaboration will focus on validating CN Bio's PhysioMimix technology for current applications in disease modelling, toxicity testing and absorption, distribution, metabolism and excretion (ADME) studies. Following successful validation, the companies will work together to adopt the platform in priority R&D areas and co-develop novel applications to expand the capabilities of OOC technologies. Pharmaron is a global drug R&D service platform, providing end-to-end services across drug discovery, preclinical, and clinical development. Through the partnership, CN Bio will install PhysioMimix instruments at Pharmaron's facilities across the globe, enabling the joint development of cutting-edge OOC solutions tailored to evolving R&D challenges. Dr Paul Brooks, CEO, CN Bio, said: 'Pharmaron is a global, premier and trusted service provider for the life sciences industry. As such, Pharmaron were the ideal partner for CN Bio as we look to accelerate the growth of our OOC solutions portfolio in new and existing application areas. By working closely together and leveraging the industry-leading expertise of each company, we can share resources that enable us to progress new, innovative solutions from concept to global market deployment more effectively than ever before. Dr Tomasz Kostrzewski, CSO, CN Bio, commented: ' The developments this partnership will enable are especially important given the recent FDA announcement, outlining their plan to phase out animal testing requirement for monoclonal antibodies and other drugs with more human-relevant models. Our platform is best placed to serve current market gaps including testing for immune-mediated organ damage. Together we can expedite this key development in line with global momentum for more ethical advancements that reduce costs and improve human health.' Dr Hua Yang, CSO, Pharmaron, added: ' We are committed to continuous innovation that enhances the quality of our services and accelerates drug discovery and development. Organ-on-a-chip technology holds significant potential to advance translational science by improving our understanding of drugability at the preclinical stage. We are pleased to collaborate with CN Bio to explore how this technology can add meaningful value to our partners' development programs.'
